Inclusion of oncology biosimilars in clinical pathways is one approach to reducing costs in this therapeutic area without compromising outcomes for cancer patients. There are currently eight Food and Drug Administration (FDA)-approved oncolytic biosimilars in the US market. Patients, providers, payers, policymakers, and manufacturers are all stakeholders that will be affected by these new biosimilars—and they all influence the placement of biosimilars in clinical pathways to ensure their appropriate use.
Oncolytic biosimilars have the potential to save the healthcare system billions of dollars each year as more biologics lose exclusivity. In this white paper, EVERSANA experts explore the biosimilar market implications for each stakeholder and how to ensure this cost savings.
Author
Craig manages the Clinical Services Department at EVERSANA ENGAGE, which comprises medical directors who have clinical, academic, research, and agency experience spanning a range of therapeutic areas. He brings to this position 25 years…
Chief Medical Director
Richard has focused his career on improving health outcomes, especially for some of the most vulnerable populations. This has been achieved through several avenues, beginning with his continued active role as a treating internist/geriatrician.…
Uttama has more than 15 years of promotional medical education, managed care, and academic experience within the therapeutic areas of diabetes, oncology, neurology, hepatology, dermatology, facial aesthetics, pain management, cardiovascular disease, and vaccines. In…